AzTrials
AzTrials

Arthritis, PsoriaticPhase 2NCT01490450

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

A Phase 2 study testing BMS-945429 in people with Arthritis, Psoriatic, run by CSL Behring at 49 sites in 13 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with active Psoriatic Arthritis and an inadequate response to Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-biologic Disease modifying anti-rheumatic drugs (DMARDs). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Arthritis, Psoriatic
What is being tested?
BMS-945429
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
165 participants
Where
49 sitesin 13 countries
Study dates
Dec 2011to Jun 2015
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Must be on a stable background Methotrexate (MTX) therapy prior to Day1/Randomization. Subjects must have taken MTX for at least 3 months at a dose ≥ 15 mg/week to a maximum weekly dose of ≤ 25 mg/week, and be at a stable dose for 4 weeks prior to randomization (Day 1). Methotrexate dose ≥ 15 mg/week that was not efficacious and that was decreased due to toxicity as low as 10 mg/week is allowed
  • Inadequate response to NSAID and/or non-biologic DMARD
  • Minimum of 3 swollen and 3 tender joints
  • Active psoriatic skin lesions over minimum 3% body surface area
  • high sensitivity C-reactive protein (hsCRP) ≥ 0.3 mg/dL

Who cannot join

  • Previously received or currently receiving concomitant biologic therapy

Trial locations and contacts

49 sites in 13 countries.

49 sites in 13 countries

United States8 sites
  • East Penn Rheumatology Associates, P.C.

    Bethlehem, Pennsylvania, 18015

  • Box Arthritis And Rheumatology Of The Carolinas, Pllc

    Charlotte, North Carolina, 28210

  • Denver Arthritis Clinic

    Denver, Colorado, 80230

  • Arthritis Associates Of Mississippi

    Jackson, Mississippi, 39202

  • Health Research Of Oklahoma

    Oklahoma City, Oklahoma, 73103

  • San Diego Arthritis Medical Clinic

    San Diego, California, 92108

  • Sarasota Arthritis Research Center

    Sarasota, Florida, 34239

  • New England Research Associates, Llc

    Trumbull, Connecticut, 06611

Other trials in United States

Poland5 sites
  • Local Institution

    Bialystok, 15-351

  • Local Institution

    Dąbrówka, 62-069

  • Local Institution

    Elblag, 82-300

  • Local Institution

    Poznan, 60773

  • Local Institution

    Warsaw, 01-868

Other trials in Poland

South Africa5 sites
  • Local Institution

    Durban, KwaZulu-Natal, 4001

  • Local Institution

    Panorama, Cape Town, Western Cape, 7500

  • Local Institution

    Pinelands, Cape Town, Western Cape, 7405

  • Local Institution

    Pretoria, Gauteng, 0083

  • Local Institution

    Pretoria, Gauteng, 0084

Other trials in South Africa

Argentina4 sites
  • Local Institution

    Capital Federal, Buenos Aires, 1015

  • Local Institution

    Capital Federal, Buenos Aires, 1425

  • Local Institution

    Capital Federal, Buenos Aires, 1428

  • Local Institution

    San Miguel de Tucumán, 4000

Other trials in Argentina

Australia4 sites
  • Local Institution

    Cairns, Queensland, 4870

  • Local Institution

    Maroochydore, Queensland, 4558

  • Local Institution

    Shenton Park, Western Australia, 6008

  • Local Institution

    Woodville, South Australia, 5011

Other trials in Australia

Canada4 sites
  • Local Institution

    Montreal, Quebec, H2L 1S6

  • Centre De Rhumatologie De L Est Du Quebec

    Rimouski, Quebec, G5L 8W1

  • Centre De Recherche Musculo-Squelettique

    Trois-Rivières, Quebec, G8Z 1Y2

  • Manitoba Clinic

    Winnipeg, Manitoba, R3A 1M3

Other trials in Canada

Hungary4 sites
  • Local Institution

    Budapest, 1023

  • Local Institution

    Budapest, 1062

  • Local Institution

    Debrecen, 4012

  • Local Institution

    Veszprém, 8200

Other trials in Hungary

Germany3 sites
  • Local Institution

    Bad Nauheim, 61231

  • Local Institution

    Erlangen, 91054

  • Local Institution

    Planegg, 82152

Other trials in Germany

Mexico3 sites
  • Local Institution

    México, Aguascalientes, 20127

  • Local Institution

    Monterrey, Nuevo León, 64460

  • Local Institution

    Zapopan, Jalisco, 45190

Other trials in Mexico

Spain3 sites
  • Local Institution

    A Coruña, 15006

  • Local Institution

    Barcelona, 08036

  • Local Institution

    Seville, 41071

Other trials in Spain

Czechia2 sites
  • Local Institution

    Pardubice, 530 02

  • Local Institution

    Prague, 128 50

Other trials in Czechia

Italy2 sites
  • Local Institution

    Florence, 50139

  • Local Institution

    Naples, 80131

Other trials in Italy

Russia2 sites
  • Local Institution

    Moscow, 115522

  • Local Institution

    Yaroslavl, 150003

Other trials in Russia

About this study

Official title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Multi-Center Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection in Adults With Active Psoriatic Arthritis

The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with active Psoriatic Arthritis and an inadequate response to Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-biologic Disease modifying anti-rheumatic drugs (DMARDs).

Being tested
Placebo matching BMS-945429, BMS-945429
Medical subject headings
Arthritis, Psoriatic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Placebo matching BMS-945429Biological

    Injection, Subcutaneous, 0 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label

  • BMS-945429Biological

    Injection, Subcutaneous, 25 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label

  • BMS-945429Biological

    Injection, Subcutaneous, 100 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label

  • BMS-945429Biological

    Injection, Subcutaneous, 200 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label

Study groups in NCT01490450
Study groupRoleWhat they receive
PBO: Placebo matching BMS-945429Placebo comparatorNot described
Receives: Biological: Placebo matching BMS-945429
BMS-945429 (25mg)ExperimentalNot described
Receives: Biological: BMS-945429
BMS-945429 (100mg)ExperimentalNot described
Receives: Biological: BMS-945429
BMS-945429 (200mg)ExperimentalNot described
Receives: Biological: BMS-945429

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20)

    The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).

    Measured: At 16 weeks

Secondary outcomes (7)
  1. Percent of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response Rate

    To calculate the PASI score, the psoriasis plaques found on each body region are graded for their combined redness, thickness, and scaliness. The severity of the plaques in each region is graded on a 0 to 4 scale, with 0 meaning no involvement and 4 meaning severe involvement. Next, the amount of surface area on each body region that is covered by the plaques is calculated. The total surface area affected by psoriasis is graded from 0 to 6, with 0 meaning no involvement and 6 meaning greater than 90 percent of the region covered in plaques.

    These grades are then fed into an equation to determine the patient's PASI score. The PASI score then is used as a clinical assessment of the patient's psoriasis involvement. A person free of psoriasis has a score of 0 and the score could be as high as 72.

    PASI 75 means that the person's PASI score dropped by 75 percent as a result of the psoriasis treatment.

    Measured: Week 16 and Week 24

  2. Percent of Participants Achieving ACR50 and ACR70 Response Rate

    The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).

    Measured: Week 16 and Week 24

  3. Percent of Participants Achieving ACR20 Response Rate at Week 24

    The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).

    Measured: Week 24

  4. Percent of Participants Achieving a Health Assessment Questionnaire (HAQ) Response

    For each item, there is a four-level difficulty scale that is scored from 0 to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). There are 20 questions in eight categories of functioning - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The highest component score in each category determines the score for the category, unless aids or devices are required. Dependence on equipment or physical assistance increases a lower score to the level of 2 to more accurately represent underlying disability. The eight category scores are averaged into an overall HAQ score on a scale from zero (no disability) to three (completely disabled). The scale is not truly continuous but has 25 possible values (i.e., 0, 0.125, 0.250, 0.375 … 3).

    Response is measured by a reduction of at least 0.3 unit from baseline in HAQ index.

    Measured: Weeks 16 and Week 24

  5. Mean Change From Baseline at Week 16 in Short Form (36) [SF-36] Scores

    The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.

    Measured: Baseline and Week 16

  6. Mean Change From Baseline at Week 24 in SF-36 Scores

    The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.

    Measured: Baseline and Week 24

  7. Number of Participants With Anti-clazakizumab Antibodies

    Measured: Up to 24 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Dec 2011 (estimated)
  2. Study startDec 2011
  3. Primary completionJun 2013
  4. Study completionJun 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
165 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01490450
Sponsor's protocol ID
IM133-004
Other IDs
2011-004016-29
Status last verified
Oct 2021
First submitted
14 Nov 2011
Last updated
5 Nov 2021
Data monitoring committee
Yes

Publications

  • Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. Arthritis Rheumatol. 2016 Sep;68(9):2163-73. doi: 10.1002/art.39700.

    PubMed 27059799

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing BMS-945429 in people with Arthritis, Psoriatic, run by CSL Behring at 49 sites in 13 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 49 sites in United States, Poland, South Africa, Argentina, Australia and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 5 Nov 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20) (time frame: At 16 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01490450, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in